After an activist investor revolted against the leadership team at Aurinia Pharmaceuticals, the CEO in question is resorting to restructuring.
Aurinia on Thursday unveiled a strategic overhaul that will slash 45% of the Canadian biotech’s entire workforce.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,